Senior BD Leader for AI-Driven Clinical Trials
PhaseV
14 days+
Application generator
Turn this role into an interview — a resume and cover letter built around what this employer wants.
Get past ATS filters
Benefits offered by this job
Job summary
A leading clinical development firm is seeking a Senior Director of Business Development to cultivate strategic partnerships and lead enterprise engagements. You will be responsible for driving account growth and ensuring client satisfaction while working closely with cross-functional teams. Ideal candidates will have over 7 years of business development experience, a proven track record in closing significant deals, and strong communication skills. This role offers a competitive salary, bonus potential, and equity participation.
Qualifications
- 7+ years of enterprise business development or strategic partnerships experience in life-science software or tech-enabled services.
- Proven record of closing $1M+ ACV deals with pharma sponsors or CROs.
- Strong understanding of clinical development workflows and the role of AI/ML.
Responsibilities
- Lead full-cycle enterprise engagements from prospecting to client success.
- Build relationships with senior executives across pharma, biotech, and CROs.
- Collaborate with Product, Data Science, and medical leaders.
Skills
Enterprise business development
Strategic partnerships
Negotiating complex commercial agreements
Excellent communication
Cross-functional collaboration
Education
Advanced degree (MBA, PhD, or MD)
Job description
A leading clinical development firm is seeking a Senior Director of Business Development to cultivate strategic partnerships and lead enterprise engagements. You will be responsible for driving account growth and ensuring client satisfaction while working closely with cross-functional teams. Ideal candidates will have over 7 years of business development experience, a proven track record in closing significant deals, and strong communication skills. This role offers a competitive salary, bonus potential, and equity participation.
'/%3e%3cpath%20d='M101.744%2012.4726L102.894%2016.1947L99.0021%2013.2201L101.744%2012.4726ZM105.3%208.40937H100.488L99.0026%203.59473L97.5116%208.41047L92.7%208.40385L96.5965%2011.3834L95.1055%2016.1942L99.0021%2013.2196L101.408%2011.3834L105.3%208.40992V8.40937Z'%20fill='white'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear_5593_1381'%20x1='90'%20y1='9.44471'%20x2='99'%20y2='9.44471'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%2300AD70'/%3e%3cstop%20offset='0.998594'%20stop-color='%2300B67A'/%3e%3cstop%20offset='1'%20stop-color='%23DCDCE6'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e){kind=small}
